Amendment To The License Agreement Sample Contracts

Chimerix Inc. – Fifth Amendment to the License Agreement Effective May 13, 2002 Between Chimerix, Inc. And the Regents of the University of California for Case Nos. [...***...], [...***...] and [...***...] (May 7th, 2018)

This fifth amendment to the agreement ("Fifth Amendment") is made by and between Chimerix, Inc., a Delaware corporation having an address at 2505 Meridian Parkway, Suite 340, Durham, NC 27713 ("Chimerix"), and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, CA 94607-5200 ("University") as represented by its San Diego campus having an address at University of California San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla, CA 92093-0910 ("UCSD").

Biodel Inc. – Second Amendment to the License Agreement (March 27th, 2017)

THIS SECOND AMENDMENT (the "Second Amendment") to the License Agreement, dated as of April 2, 2012 (the "Original License Agreement"), as amended on January 30, 2015, (the "Agreement"), by and between Elobix AB ("Elobix") and EA Pharma Co., Ltd. (formerly known as Ajinomoto Pharmaceuticals Co., Ltd., "EA") is entered into on April 6, 2016. Elobix and EA may each be referred to herein individually as a "Party" and collectively as the "Parties."

Biodel Inc. – First Amendment to the License Agreement (March 27th, 2017)

THIS FIRST AMENDMENT (the "First Amendment") to the License Agreement, dated as of April 2, 2012 (the "Agreement"), by and between Albireo AB ("Albireo") and Ajinomoto Pharmaceuticals Co, Ltd. ("Ajinomoto") is entered into on January 30, 2015.

This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [* * *] and Has Been Filed Separately With the Securities and Exchange Commission. Second Amendment to the License Agreement (March 1st, 2017)

This Second Amendment ("Second Amendment"), effective as of November 7, 2016, between Acceleron Pharma Inc., having its principal place of business at 128 Sidney Street, Cambridge, MA 02139 ("Licensee") and Beth Israel Deaconess Medical Center, having its principal place of business at 330 Brookline Avenue, Boston, MA 02215 (the "BIDMC") amends the License Agreement between BIDMC and Licensee, dated June 21, 2012 as amended on October 6, 2015 (the "Agreement"). Together BIDMC and Licensee are the "Parties" and each is a "Party".

Second Amendment to the License Agreement Between the Regents of the University of California and Chromadex Inc. (November 10th, 2016)

This second amendment (the "Second Amendment"), dated December 31st, 2015 (the "Effective Date"), is made by and between The Regents of the University of California ("The Regents"), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Irvine located at 5171 California Ave, Suite 150 CA 92697-7700 and ChromaDex Inc. ("Licensee") having a principal place of business at 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 and amends the license agreement with Licensee, dated September 8, 2011 with UC Agreement Control Number 2012-04-0120 (the "License Agreement").

First Amendment to the License Agreement (October 27th, 2016)

This First Amendment to the License Agreement (the "First Amendment") is made and entered into as of September 20, 2016 (the "First Amendment Effective Date") by and between Sangamo BioSciences, Inc., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 ("Sangamo"), and Open Monoclonal Technology, Inc., a Delaware corporation with offices at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121 ("OMT"). OMT and Sangamo are individually referred to herein as a "Party" or collectively as the "Parties".

Inksure Technologies – First Amendment to the License Agreement (October 18th, 2016)

This First Amendment to the License Agreement (this "Amendment") is entered into on July 27, 2016 by and between Hadasit Medical Research Services & Development Ltd., of Jerusalem Bio Park, Hadassah Ein-Kerem Medical Center, P.O.B. 12000, Jerusalem 91120, Hong Kong University of Science and Technology R and D Corporation Limited, and Artemis Therapeutics Inc., a Delaware corporation, having a place of business at 1633 Broadway, New York, NY 10019 (collectively, the "Parties" or each a "Party").

Bone Biologics, Corp. – Tenth Amendment to the License Agreement (June 14th, 2016)

THIS TENTH AMENDMENT (the "Tenth Amendment"), dated June 3, 2016 (the "Tenth Amendment's Effective Date"), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ("The Regents"), a California corporation having its statewide administrative offices at IIII Franklin Street, 12" Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and BONE BIOLOGICS CORPORATION ("Licensee") having a principal place of business at 321 Columbus Avenue, Boston, MA 02116 and amends the Exclusive License Agreement with Licensee, dated March 15, 2006 with UC Agreement Control Number 2006-03-0536 as amended by the First Amendment dated September 1,2007 with UC Control Number 2006-03-0536F, as further amended by the Second Amendment dated May 29, 2008 with UC Control Number 2006-03-05361, as further amended by the Third Amendment dated December 4, 2008 with UC Control Numbe

Kadmon Holdings, LLC – First Amendment to the License Agreement (June 10th, 2016)

This First Amendment to the License Agreement (this Amendment) is made and entered into as of the 22nd day of May, 2014 (the Effective Date), by and among Kadmon Pharmaceuticals, LLC, a Pennsylvania limited liability company (Kadmon) and AbbVie Inc., a Delaware corporation (AbbVie). Kadmon and AbbVie may be referred to herein individually as a Party or collectively as the Parties.

Kadmon Holdings, LLC – Third Amendment to the License Agreement (June 10th, 2016)

This THIRD AMENDMENT dated as of May , 2015 (this Third Amendment) to that certain License Agreement by and between Kadmon Pharmaceuticals, LLC (Kadmon) and AbbVie Inc., (AbbVie) dated June 17, 2013 as amended,(the License Agreement), is made by and between Kadmon and AbbVie. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the License Agreement.

Pulse Biosciences, Inc. – Amendment to the License Agreement (May 3rd, 2016)

This Amendment to the License Agreement (the Amendment) is effective this 8th day of September, 2014 (the Effective Date) between THE UNIVERSITY OF SOUTHERN CALIFORNIA, a California nonprofit corporation (USC); ALFRED E. MANN INSTITUTE FOR BIOMEDICAL ENGINEERING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA, a Delaware corporation (AMI-USC); and ElectroBlate, a Nevada Corporation (ELECTROBLATE).

Pulse Biosciences, Inc. – Amendment to the License Agreement (March 28th, 2016)

This Amendment to the License Agreement (the "Amendment") is effective this 8th day of September, 2014 (the "Effective Date") between THE UNIVERSITY OF SOUTHERN CALIFORNIA, a California nonprofit corporation ("USC"); ALFRED E. MANN INSTITUTE FOR BIOMEDICAL ENGINEERING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA, a Delaware corporation ("AMI-USC"); and ElectroBlate, a Nevada Corporation ("ELECTROBLATE").

Kadmon Holdings, LLC – First Amendment to the License Agreement (March 18th, 2016)

This First Amendment to the License Agreement (this Amendment) is made and entered into as of the 22nd day of May, 2014 (the Effective Date), by and among Kadmon Pharmaceuticals, LLC, a Pennsylvania limited liability company (Kadmon) and AbbVie Inc., a Delaware corporation (AbbVie). Kadmon and AbbVie may be referred to herein individually as a Party or collectively as the Parties.

Kadmon Holdings, LLC – Third Amendment to the License Agreement (March 18th, 2016)

This THIRD AMENDMENT dated as of May , 2015 (this Third Amendment) to that certain License Agreement by and between Kadmon Pharmaceuticals, LLC (Kadmon) and AbbVie Inc., (AbbVie) dated June 17, 2013 as amended,(the License Agreement), is made by and between Kadmon and AbbVie. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the License Agreement.

Pulse Biosciences, Inc. – Amendment to the License Agreement (March 7th, 2016)

This Amendment to the License Agreement (the "Amendment") is effective this 8th day of September, 2014 (the "Effective Date") between THE UNIVERSITY OF SOUTHERN CALIFORNIA, a California nonprofit corporation ("USC"); ALFRED E. MANN INSTITUTE FOR BIOMEDICAL ENGINEERING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA, a Delaware corporation ("AMI-USC"); and ElectroBlate, a Nevada Corporation ("ELECTROBLATE").

XTL Biopharmaceuticals Ltd. – FIRST AMENDMENT TO THE LICENSE Agreement (December 31st, 2015)

a company duly registered under the laws of Israel, having its principal place of business at 5 Hacharoshet St., Raanana 43656, Israel

Bone Biologics, Corp. – NINTH AMENDMENT TO THE LICENSE AGREEMENT UC Control No. 2006-03-0536 (December 30th, 2015)

THIS NINTH AMENDMENT (the "Ninth Amendment"), date December 22, 2015 (the "Ninth Amendment Effective Date"), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ("The Regents"), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and BONE BIOLOGICS CORPORATION ("Licensee'') having a principal place of business at 321 Columbus Ave., Boston, MA 02116 and amends the Exclusive License Agreement with Licensee, dated March 15, 2006 with UC Agreement Control Number 2006-03-0536 as amended by the First Amendment dated September 1, 2007 with UC Control Number 2006-03-0536F, as further amended by the Second Amendment dated May 29, 2008 with UC Control Number 2006-03-0536I, as further amended by the Third Amendment dated December 4, 2008 with UC Control Nu

sEVENTH AMENDMENT TO THE LICENSE AGREEMENT (August 6th, 2015)

This SEVENTH AMENDMENT TO THE LICENSE AGREEMENT (the "Seventh Amendment") is made and entered into as of January 1, 2015 (the "Seventh Amendment Effective Date"), by and between SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 ("Sangamo"), and SIGMA-ALDRICH CO., LLC, a Delaware limited liability company having its principal place of business at 3050 Spruce Street, St. Louis, MO 63103 ("Sigma"). Sigma and Sangamo are individually referred to herein as a "Party" or collectively as the "Parties."

SIXTH AMENDMENT TO THE LICENSE AGREEMENT UC Control No. 2006-04-0026 (July 9th, 2015)

THIS SIXTH AMENDMENT (the "Sixth Amendment"), dated July 8, 2015, (the "Sixth Amendment Effective Date"), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ("The Regents"), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles, located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 (the "Institution"), and PUTNEY DRUG CORP. ("Licensee"), having a principal place of business at 617 Detroit Street, Suite 100, Ann Arbor, MI 48104, and amends the Exclusive License Agreement, dated June 11, 2005, between Licensee and The Regents with UC Agreement Control No. 2006-04-0026 (the "Original License Agreement") and subsequent amendments thereto (collectively, the "License Agreement") in accordance with the terms and conditions of this Sixth Amendment. The Regents and Licensee may be referred to herein individu

FIFTH AMENDMENT TO THE LICENSE AGREEMENT UC Control No. 2006-04-0026 (July 9th, 2015)

THIS FIFTH AMENDMENT (the "Fifth Amendment"), dated July 25, 2014 (the "Effective Date"), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA("The Regents"), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and PUTNEY DRUG CORP. ("Licensee") having a principal place of business at 155 Gibbs Street, Suite 412, Rockville, MD 20850 amends the Exclusive License Agreement ,dated June 11 2005, between the Licensee and The Regents with UC Agreement Control No. 2006-04-0026 and subsequent amendments (collectively, the "License Agreement") in accordance with the terms and conditions of this Fifth Amendment.

First Amendment to the License Agreement Between the Regents of the University of California and Chromadex Inc. (November 6th, 2014)

This first amendment (the "First Amendment"), dated Sept 5th, 2014 (the "Effective Date"), is made by and between The Regents of the University of California ("The Regents"), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Irvine located at 5171 California Ave, Suite 150 CA 92697-7700 and ChromaDex Inc. ("Licensee") having a principal place of business at 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 and amends the license agreement with Licensee, dated September 8, 2011 with UC Agreement Control Number 2012-04-0120 (the "License Agreement").

First Amendment to the License Agreement Effective as of December 29, 2003 Between XOMA Ireland Limited and Diversa Corporation (November 6th, 2014)

This first amendment ("First Amendment") to the License Agreement effective as of December 29, 2003 between XOMA Ireland Limited (assigned to XOMA (US) LLC) and Verenium Corporation (formerly known as Diversa Corporation and assigned to BP) (the "Agreement") is entered into by and between XOMA (US) LLC, a Delaware company with limited liability ("XOMA"), and BP Biofuels Advanced Technology Inc., a Delaware corporation ("BP") on October 28, 2014 (the "First Amendment Effective Date").

Sixth AMENDMENT TO THE LICENSE AGREEMENT (October 28th, 2014)

This SIXTH AMENDMENT TO THE LICENSE AGREEMENT (the "Sixth Amendment") is made and entered into as of September 2, 2014 (the "Sixth Amendment Effective Date"), by and between SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 ("Sangamo"), and SIGMA-ALDRICH CO., LLC, a Delaware limited liability company having its principal place of business at 3050 Spruce Street, St. Louis, MO 63103 ("Sigma"). Sigma and Sangamo are individually referred to herein as a "Party" or collectively as the "Parties."

Amendment No. 4 to the License Agreement Effective 04/15/2001 Between Stanford University and Histogenics Corporation (October 7th, 2014)

Effective as of April 29, 2010, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (Stanford), an institution of higher education having powers under the laws of the State of California, and Histogenics Corporation, a Delaware corporation having its principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (Histogenics) agrees as follows:

NeuroSigma, Inc. – The COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE COMMISSION) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT AND FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH *****. FIRST AMENDMENT TO THE LICENSE AGREEMENT UC Control No. 2011-04-0059 (August 26th, 2014)

This first amendment (the First Amendment), dated January 9, 2011 (the Effective Date), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (The Regents), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and NEUROSIGMA, INC. (Licensee) having a principal place of business at 10960 Wilshire Boulevard, Suite 1230, Los Angeles, CA, 90024 and amends the license agreement with Licensee, dated July 26, 2010 with UC Agreement Control Number 2011-04-0059 (the License Agreement), in accordance with the terms and conditions of this First Amendment.

NeuroSigma, Inc. – The COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE COMMISSION) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT AND FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH *****. THIRD AMENDMENT TO THE LICENSE AGREEMENT UC Control No. 2011-04-0059 (August 26th, 2014)

THIS THIRD AMENDMENT (the Third Amendment), dated August 30, 2012 (the Effective Date), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (The Regents), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and NEUROSIGMA, INC. (Licensee) having a principal place of business at 10960 Wilshire Boulevard., Suite 1230, Los Angeles, CA, 90024 and amends the license agreement with Licensee, dated July 26, 20 l 0 with UC Agreement Control Number 2011-04-0059, the First Amendment dated January 9, 2011, and the Second Amendment dated July 29, 2011 (the License Agreement), in accordance with the terms and conditions of this Third Amendment.

NeuroSigma, Inc. – The COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE COMMISSION) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT AND FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH *****. SECOND AMENDMENT TO THE LICENSE AGREEMENT UC Control Number 2011-04-0059 (August 26th, 2014)

THIS SECOND AMENDMENT (the Second Amendment), dated July 29, 2011 (the Effective Date), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (The Regents), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and NEUROSIGMA, INC. (Licensee) having a principal place of business at 10960 Wilshire Boulevard., Suite 1230, Los Angeles, CA, 90024 and amends the license agreement with Licensee, dated July 26, 2010 with UC Control Number 2011-04-0059 (the License Agreement) as amended by the first amendment dated January 9, 2011 with UC Control Number 2011-04-0059C (such amendment are also part of the License Agreement for purposes of this agreement) in accordance with the terms and conditions of this Second Amendment.

Fifth Amendment to the License Agreement (May 9th, 2013)

This FIFTH AMENDMENT TO THE LICENSE AGREEMENT (the Fifth Amendment) is made and entered into as of April 1, 2013 (the Fifth Amendment Effective Date), by and between SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (Sangamo), and SIGMA-ALDRICH CO., LLC, a Delaware limited liability company having its principal place of business at 3050 Spruce Street, St. Louis, MO 63103 (Sigma). Sigma and Sangamo are individually referred to herein as a Party or collectively as the Parties.

Second Amendment to the License Agreement Between the Regents of the University of California and General Fiber, Inc. License Agreement Control No. 2006-04-0026 Effective January 3, 2007 (April 16th, 2013)

This Second Amendment (the "Second Amendment") dated January 3, 2007 is made by and between The Regents of the University of California and General Fiber, Inc.

First Amendment to the License Agreement Between the Regents of the University of California and General Fiber, Inc. UC Agreement Control No. 2006-04-0026 (April 16th, 2013)

This First Amendment ("First Amendment"), dated November 08, 2005 (the "Effective Date"), is made by and between The Regents of the University of California ("The Regents") and General Fiber, Inc. ("Licensee").

Fourth Amendment to the License Agreement (November 2nd, 2012)

This FOURTH AMENDMENT TO THE LICENSE AGREEMENT (the Fourth Amendment) is made and entered into as of September 14, 2012 (the Fourth Amendment Effective Date) by and between SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (Sangamo), and SIGMA-ALDRICH CO. LLP, a Delaware limited liability company having its principal place of business at 3050 Spruce Street, St. Louis, MO 63103 (Sigma). Sigma and Sangamo are individually referred to herein as a Party or collectively as the Parties.

Health Discovery Cp – First Amendment to the License Agreement (November 14th, 2011)

This First Amendment to the License Agreement ("First Amendment") is entered into, and made effective on, August 4, 2011 by and between Health Discovery Corporation, a Georgia corporation ("HDC"), having its principal place of business at 2 East Bryan Street, Suite #610, Savannah, GA 31401 ("HDC"), and Abbott Molecular Inc., a Delaware corporation having its principal place of business at 1300 East Touhy Avenue, Des Plaines, IL, 60018 ("Abbott"), collectively referred to as the "Parties."

Fifth Amendment to the License Agreement (October 31st, 2011)

This FIFTH AMENDMENT (this Fifth Amendment) to the License Agreement dated July 14, 2004, as thereafter amended (the Agreement) by and between Vernalis Development Limited (Vernalis) and Endo Pharmaceuticals Inc. (Endo), is entered into as of August 15, 2011 (the Fifth Amendment Effective Date) . Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Agreement.

United States Natural Gas Fd – Third Amendment to the License Agreement (October 24th, 2011)

This Third Amendment (Amendment) dated as of October 20, 2011 is by and among the New York Mercantile Exchange, Inc. (NYMEX), United States Commodity Funds LLC (USCF) as General Partner to the Funds listed in ATTACHMENT A hereto (the Funds) and the Funds.

United States Gasoline Fd Lp – Third Amendment to the License Agreement (October 24th, 2011)

This Third Amendment (Amendment) dated as of October 20, 2011 is by and among the New York Mercantile Exchange, Inc. (NYMEX), United States Commodity Funds LLC (USCF) as General Partner to the Funds listed in ATTACHMENT A hereto (the Funds) and the Funds.